US FDA approves over-the-counter Tylenol combination pill for pain relief

July 24, 2026 12:00 PM EDT

FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

July 24 (Reuters) - The ‌U.S. Food ​and ​Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's Tylenol ‌with the nonsteroidal anti-inflammatory drug naproxen for ⁠up to 12 hours of pain relief.

Here are some details:

• ‌The pill can be ‌used by adults and children aged 12 and older for headaches, back pain, muscle aches, ​toothaches, menstrual cramps and minor arthritis pain.

• The FDA said the approval aligns with Trump's "The ⁠Great Healthcare Plan," a federal effort to make more verified safe ​pharmaceutical drugs available for over-the-counter purchase.

• Each pill contains 325 milligrams of Tylenol ​and 110 milligrams of naproxen ‌sodium.

• Tylenol has been under scrutiny after U.S. health officials raised concerns about ⁠an alleged link between Tylenol use during pregnancy and autism. There is no firm scientific evidence of ⁠such a link.

• The debate has also triggered legal action, ​as Texas sued Kenvue over alleged failures to warn pregnant consumers, and a U.S. appeals court this month ‌revived more than 500 private lawsuits making similar claims.

• Kenvue agreed last November ‌to be acquired by Kleenex tissue maker Kimberly-Clark ⁠for more than $40 ‌billion. The transaction ​is expected to close this year.

(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim ‌Zahid)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters

Related Entities

FDA